

Biotechnology, Healthcare & Medical Informatics Business



Promoted Selection and Concentration of Business Based on Advancements in Research and Development

The Environment Surrounding Biotechnology, Healthcare & Medical Informatics Business

Amid growing awareness toward health following the spread of the COVID-19 virus, the SBI Group is accelerating the development of new foods with function claims using 5-ALA. In addition, the SBI Group considers the medical informatics field to be a new pillar of future business growth because of the low degree of accuracy of medical statistical data as well as the need for the digitalization of medical data and utilization of big data.

Principal Companies

SBI ALApharma
SBI Biotech
Quark Pharmaceuticals ("Quark")
SBI Pharmaceuticals
SBI ALApromo
photonamic
NX Development Corp.
SBI ALApharma Canada
Photonics Healthcare
Medical Data Vision

Full-year Profit (Loss) before Income Tax Expense of the Biotechnology, Healthcare & Medical Informatics Business (Based on IFRSs)

(Millions of yen)

	FY2019	FY2020
SBI Biotech	16	(278)
Quark Pharmaceuticals	(7,668)	(4,234)
SBI Pharmaceuticals	(1,272)	(1,726)
5-ALA related business		
SBI ALApromo	193	348
photonamic	173	71
Medical Data Vision (Equity method affiliate)		36

Principal Initiatives and Priority Measures in FY2020

- The segment name has changed to "Biotechnology, Healthcare & Medical Informatics Business" from Q3 FY2020 after entering the medical informatics field by acquiring Medical Data Vision Co., Ltd. as an equity method affiliate.

> SBI Biotech

- Making steady progress with the development of out-licensed pipeline drugs and achieved the milestone for SBI-9674 licensed out to Kyowa Kirin in 2016.

> Quark Pharmaceuticals

- Decision were made to withdraw from the business
- Froze new development and promoted greater cost reductions including rightsizing the workforce for the minimum necessary business size.
- Prioritizing the sale of its stock, the company commenced negotiations with multiple candidates. The company is also looking to sell off its intellectual properties at the same time.

> 5-ALA-related business

- SBI Pharmaceuticals completed phase III clinical trials for mitochondrial diseases in April 2021.
- SBI Pharmaceuticals and photonamic cooperated with a joint trial with Royal College of Surgeons in Ireland and Medical University of Bahrain for the use of 5-ALA in COVID-19 patients as well case study at Showakai Medical Corporation Hanzomon Gastrointestinal Clinic.
- SBI ALApromo rapidly increased sales of 5-ALA related products following growing health consciousness due to COVID-19.

> Medical Data Vision Co., Ltd.

- Entered into the medical informatics field by acquiring Medical Data Vision Co., Ltd. as an equity method affiliate in November 2020.

5-ALA related Products

Ethical drug



ALAGLIO®
Divided Granules 1.5g

Health foods and cosmetics



ALA PLUS
Gold EX



ALA PLUS Tou
(Sugar) Down



ALA PLUS Fukai Nemuri
(Deep Sleep)



ALA PLUS
Karada Active



ALA PLUS
Karada Shape



ALA PLUS
Cosmetic Series

Note: Products sold as of the end of June 2021